A detailed history of Macquarie Group LTD transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 5,700 shares of VYGR stock, worth $30,552. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,700
Previous 5,700 -0.0%
Holding current value
$30,552
Previous $45,000 26.67%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$2.75 - $9.44 $1,278 - $4,389
-465 Reduced 7.54%
5,700 $43,000
Q1 2021

May 14, 2021

SELL
$4.61 - $9.04 $1,014 - $1,988
-220 Reduced 3.45%
6,165 $29,000
Q2 2020

Aug 11, 2020

BUY
$8.05 - $14.21 $5,514 - $9,733
685 Added 12.02%
6,385 $81,000
Q1 2019

May 15, 2019

BUY
$8.0 - $19.66 $43,200 - $106,164
5,400 Added 1800.0%
5,700 $109,000
Q3 2018

Nov 15, 2018

SELL
$17.11 - $21.74 $29,087 - $36,958
-1,700 Reduced 85.0%
300 $6,000
Q2 2018

Aug 14, 2018

BUY
$16.76 - $23.92 $33,520 - $47,840
2,000 New
2,000 $39,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $207M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.